Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.

Patients with LGG have a higher VTE risk compared to the general population, which is decreased, but not eliminated, in the presence of an IDH mutation. MGMT promoter methylation in glioblastoma does not affect the incidence of VTE.